Home › Research › Getting a diagnosis
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL et al.. Neurology, 2010-12-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Objectives This is a cross-sectional, observational study to determine the frequency and associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse sample of infected individuals in the era of combination antiretroviral therapy (CART). Methods A total of 1,555 HIV-infected adults were recruited from 6 university clinics across the United States, with minimal exclusions. We used standardized neuromedical, psychiatric, and neuropsychological (NP) examinations, and recently published criteria for diagnosing HAND and classifying 3 levels of comorbidity (minimal to severe non-HIV risks for NP impairment). Results Fifty-two percent of the total sample had NP impairment, with higher rates in groups with greater comorbidity burden (40%, 59%, and 83%). Prevalence estimates for specific HAND diagnoses (excluding severely confounded cases) were 33% for asymptomatic neurocognitive impairment, 12% for mild neurocognitive disorder, and only 2% for HIV-associated dementia (HAD). Among participants with minimal comorbidities (n = 843), history of low nadir CD4 was a strong predictor of impairment, and the lowest impairment rate on CART occurred in the subset with suppressed plasma viral loads and nadir CD4 ≥200 cells/mm(3) (30% vs 47% in remaining subgroups). Conclusions The most severe HAND diagnosis (HAD) was rare, but milder forms of impairment remained common, even among those receiving CART who had minimal comorbidities. Future studies should clarify whether early disease events (e.g., profound CD4 decline) may trigger chronic CNS changes, and whether early CART prevents or reverses these changes.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 843 participants. This cross-sectional study found that HIV-associated neurocognitive disorders remain common in the era of combination antiretroviral therapy, with 52% of the sample showing neuropsychological impairment and only 2% having HIV-associated dementia. It concerns cognitive impairment in HIV-infected adults, not the treatment, cure, or prevention of Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Heaton, R. K., Clifford, D. B., Franklin, D. R., Woods, S. P., Ake, C., Vaida, F., et al. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. https://doi.org/10.1212/wnl.0b013e318200d727
Vancouver
Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010. doi:10.1212/wnl.0b013e318200d727. PMID: 21135382.
BibTeX
@article{heaton2010-21135382,
author = {Heaton, R. K. and Clifford, D. B. and Franklin, D. R. and Woods, S. P. and Ake, C. and Vaida, F. and Ellis, R. J. and Letendre, S. L. and others},
title = {{HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study}},
journal = {Neurology},
year = {2010},
doi = {10.1212/wnl.0b013e318200d727},
pmid = {21135382},
url = {https://doi.org/10.1212/wnl.0b013e318200d727}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Fifty-two percent of the total sample had NP impairment, with higher rates in groups with greater comorbidity burden (40%, 59%, and 83%).
Why it matters
This cross-sectional study found that HIV-associated neurocognitive disorders remain common in the era of combination antiretroviral therapy, with 52% of the sample showing neuropsychological impairment and only 2% having HIV-associated dementia. It concerns cognitive impairment in HIV-infected adults, not the treatment, cure, or prevention of Alzheimer's disease.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designcross-sectional
- Participants843
- Evidence strengthLow
How this study scored 64/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 61 of the 96 points we could judge it on, which is 64 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 843 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 2,351 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 130.6 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 5 / 6 | Cited 35.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 4 / 4 | Cited 299 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21135382) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 61 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 61 of the 96 points we could judge it on is 64 out of 100. |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Getting a diagnosis from nearby years
Also tagged “small”
900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.